Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sunitinib rechallenge as third-line therapy in metastatic renal cancer
2012-000473-23Phase 2Completed
- Sponsor
- Gruppo Italiano Oncologia Nefrologica
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC), sponsored by Gruppo Italiano Oncologia Nefrologica. Primary endpoint: Freedom from disease progression. Started Mar 2012; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2012-000473-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000473-23.